Approaches to rapid acting insulin intensification in patients with type 2 diabetes mellitus not achieving glycemic targets

References

• Centers for Disease Control and Prevention [Internet]. More than 29 million Americans have diabetes; 1 in 4 doesn’t know [cited 2016 Sep 28]. Available from: http://www.cdc.gov/media/releases/2014/p0610-diabetes-report.html
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Dia Care. 2015;38:140–149.
   PubMed Web of Science ®Google Scholar
• U.K. Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease. Diabetes. 1995;44:1249–1258.
   PubMed Web of Science ®Google Scholar
• Ross SA. Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes. Am J Med. 2013;126:S38–S48.
   PubMed Web of Science ®Google Scholar
• Khunti K, Nikolajsen A, Thorsted BL, et al. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18:401–409.
   PubMed Web of Science ®Google Scholar
• Chamberlain JJ, Herman WH, Leal S, et al. Pharmacologic therapy for type 2 diabetes: synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. 2017;166:572–578.
   PubMed Web of Science ®Google Scholar
• Fulcher G, Roberts A, Sinha A, et al. What happens when patients require intensification from basal insulin? A retrospective audit of clinical practice for the treatment of type 2 diabetes from four Australian centres. Diabetes Res Clin Pract. 2015;108:405–413.
   PubMed Web of Science ®Google Scholar
• Hinnen DA. Therapeutic options for the management of postprandial glucose in patients with type 2 diabetes on basal insulin. Clin Diabetes. 2015;33:175–180.
   PubMedGoogle Scholar
• Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–3086.
   PubMed Web of Science ®Google Scholar
• Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists. Diabetes Care. 2011;34:S279–S284.
   PubMed Web of Science ®Google Scholar
• Vora J. Combining incretin-based therapies with insulin. Diabetes Care. 2013;36:S226–S232.
   PubMed Web of Science ®Google Scholar
• Raccah D, Lin J, Wang E, et al. Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. J Diabetes Complications. 2014;28:40–44.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Fonseca VA, Gross JL, et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care. 2014;37:2317–2325.
   PubMed Web of Science ®Google Scholar
• Billings LK, Doshi A, Gouet D, et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin; DUAL VII randomized clinical trial. Diabetes Care. 2018;41:1009–1016.
   PubMed Web of Science ®Google Scholar
• Gallwitz B, Dagogo-Jack S, Thieu V, et al. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Diabetes Obes Metab. 2018;20:409–418.
   PubMed Web of Science ®Google Scholar
• Giorgino F, Bonadonna RC, Gentile S, et al. Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists. Diabetes Metab Res Rev. 2016;32:497–511.
   PubMed Web of Science ®Google Scholar
• Raccah D. Basal insulin treatment intensification in patients with type 2 diabetes mellitus: a comprehensive systematic review of current options. Diabetes Metab. 2017;43:110–124.
   PubMed Web of Science ®Google Scholar
• Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–1747.
   PubMed Web of Science ®Google Scholar
• Darmon P, Raccah D. Options for intensification of basal insulin in type 2 diabetes: premeal insulin or short-acting GLP-1 receptor agonists? Diabetes Metab. 2015;41:6S21–6S27.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Visco VE, Andersen H, et al. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol. 2014;2:30–37.
   PubMed Web of Science ®Google Scholar
• Meneghini L, Mersebach H, Kumar S, et al. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Endocr Pract. 2011;17:727–736.
   PubMed Web of Science ®Google Scholar
• Edelman SV, Liu R, Johnson J, et al. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes. Diabetes Care. 2014;37:2132–2140.
   PubMed Web of Science ®Google Scholar
• Malek R, Ajili F, Assaad-Khalil SH, et al. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: results of a 50-week randomized clinical trial of stepwise insulin intensification. Diabetes Metab. 2015;41:223–230.
   PubMed Web of Science ®Google Scholar
• Davidson MB, Raskin P, Tanenberg RJ, et al. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract. 2011;17:395–403.
   PubMed Web of Science ®Google Scholar
• Deshpande PR, Rajan S, Sudeepthi BL, et al. Patient-reported outcomes: a new era in clinical research. Perspect Clin Res. 2011;2:137–144.
   PubMedGoogle Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2017. Diabetes Care. 2017;40:S1–S135.
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists and American College of Endocrinology [Internet]. Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015 [cited 2017 Accessed November]. Available from: https://www.aace.com/files/dm-guidelines-ccp.pdf
   Google Scholar
• Khunti K, Davies MJ, Kalra S. Self-titration of insulin in the management of people with type 2 diabetes: a practical solution to improve management in primary care. Diabetes Obes Metab. 2013;15:690–700.
   PubMed Web of Science ®Google Scholar
• Schnell O, Hanefeld M, Monnier L. Self-monitoring of blood glucose: a prerequisite for diabetes management in outcome trials. J Diabetes Sci Technol. 2014;8:609–614.
   PubMedGoogle Scholar
• Abrahamson MJ, Peters A. Intensification of insulin therapy in patients with type 2 diabetes mellitus: an algorithm for basal-bolus therapy. Ann Med. 2012;44:836–846.
   PubMed Web of Science ®Google Scholar
• Bailey T, Bode BW, Christiansen MP, et al. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015;17:787–794.
   PubMed Web of Science ®Google Scholar
• Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167:365–374.
   PubMed Web of Science ®Google Scholar